Studies have demonstrated menstrual cycle influences on basal pain perception, but direct evidence of menstrual cycle influences on analgesic responses has not been reported in humans. Our aim was to determine whether the magnitude of morphine and pentazocine analgesia varied across the menstrual cycle. Sixty-five healthy women, 35 taking oral contraceptives (OC) and 30 normally cycling (NOC), underwent experimental pain assessment both before and after intravenous administration morphine (0.08 mg/kg) or pentazocine (0.5 mg/kg) compared to saline placebo. Both active drug and placebo were administered once during the follicular phase and once during the luteal phase. Measures of heat, ischemic, and pressure pain sensitivity were obtained before and after drug administration. Change scores in pain responses were computed to determine morphine and pentazocine analgesic responses, and medication side effects were recorded. The data were analyzed using mixed-model analyses of variance. NOC women showed slightly greater heat pain sensitivity in the follicular vs luteal phase, while the reverse pattern emerged for OC women (P = 0.046). Also, OC women showed lower pressure pain thresholds compared to NOC women (P < 0.05). Regarding analgesic responses, NOC women showed greater morphine analgesia for ischemic pain during the follicular vs the luteal phase (P = 0.004). Likewise, side effects for morphine were significantly higher in NOC women in the follicular phase than in the luteal phase (P = 0.02). These findings suggest that sex hormones may influence opioid responses; however, the effects vary across medications and pain modalities and are likely to be modest in magnitude.
Introduction
The body is widely responsive to gonadal steroid hormones. Aside from their reproductive functions, gonadal hormones act on nervous system regions involved in higher cognitive functions such as mood, motor behavior, and pain mechanisms [33] . For example, pregnancy-related changes in reproductive hormone levels increase pain thresholds and decrease anesthesia requirements in humans and some nonhuman animals; a phenomenon that can be recreated by hormonal simulation in nonpregnant animals [22, 41] . The influence of gonadal hormones, particularly estrogens, has been implicated as a potential mechanism for explaining sex differences in both basal pain sensitivity and opioid analgesia [14, 15] .
Barring several exceptions, evidence suggests that male rats exhibit more robust antinociception than females in response to l-receptor selective (eg, hydromorphone, buprenorphine) and j-receptor selective agonists (eg, U50,488) [6,7,29,38] . Moreover, early hormone manipulation of fetal and neonate rodents (eg, male castration, female ovariectomy, hormone augmentation) has lasting effects on morphine dose-response curves [3, 5] . In contrast to these organizational hormonal influences, research investigating the acute activational effects of gonadal hormones on responses to opioid administration in nonhuman animals has yielded inconsistent results [10] . For example, several studies have found that morphine and buprenorphine antinociception increased in ovariectomized female rats, whereas chronic estrogen (E2) replacement decreased morphine potency to levels similar to those seen in intact females, suggesting that hormone depletion in adulthood might modulate opioid potency [44, 45] . Similarly, Ali et al. [1] showed that gonadectomized male and female rats showed greater morphine antinociception than their intact counterparts. In contrast, Cicero et al. [5] noted that gonadectomized adult male and female rats displayed no significant changes in the expected sex differences in morphine-induced antinociception.
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